BSE Limited
25th Floor, Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai 400 001
India

Fax: +91 22 2272 1919
Tel: +91 22 2272 1233 / 4, +91 22 6654 5695

26 March 2020

Dear Sir/Madam:

Enclosed please find a copy of regulatory filing for Cyient Limited.

- Regulatory filing required under regulation 29 (2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulation 2011

If you have any questions, please contact us directly by email apac.regulatory.filings@fil.com or by fax at +852 2629 9669.

Yours faithfully,

[Signature]

Regulatory Reporting, Asia Pacific

Encl.
Format for disclosures under Regulation 29(2) of SEBI
(Substantial Acquisition of Shares and Takeovers) Regulations, 2011

<table>
<thead>
<tr>
<th>Name of the Target Company (TC)</th>
<th>Cyient Limited</th>
</tr>
</thead>
<tbody>
<tr>
<td>Name(s) of the acquirer and Persons Acting in Concert (PAC) with the acquirer</td>
<td>See attached Schedule for breakdown of funds under management of FMR LLC and its direct and indirect subsidiaries and FIL Limited and its direct and indirect subsidiaries</td>
</tr>
<tr>
<td>Whether the acquirer belongs to Promoter/Promoter group</td>
<td>No</td>
</tr>
<tr>
<td>Name(s) of the Stock exchange(s) where the shares of TC are Listed</td>
<td>National Stock Exchange of India Ltd.</td>
</tr>
<tr>
<td>Details of the acquisition as follows</td>
<td>Number</td>
</tr>
</tbody>
</table>

**Before the acquisition/disposal under consideration, holding of:**

a) Shares carrying voting rights

b) Shares in the nature of encumbrance (pledge/ lien/ non-disposal undertaking/ others)

c) Voting rights (VR) otherwise than by shares

d) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category)

e) Total (a+b+c+d) / /14,861 / /.03% N/A

**Details of acquisition/sale**

a) Shares carrying voting rights acquired

b) VRs acquired otherwise than by shares

c) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) acquired
<table>
<thead>
<tr>
<th>d) Shares encumbered/ invoked/ released by the acquirer/ seller</th>
<th>32,600</th>
<th>0.03%</th>
<th>N/A</th>
</tr>
</thead>
<tbody>
<tr>
<td>c) Total (a+b+c+d)</td>
<td>7,747,560</td>
<td>7.05%</td>
<td>N/A</td>
</tr>
<tr>
<td>After the acquisition/sale, holding of:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>a) Shares carrying voting rights</td>
<td>7,747,560</td>
<td>7.05%</td>
<td>N/A</td>
</tr>
<tr>
<td>b) Shares encumbered with the acquirer</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>c) VRs otherwise than by shares</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>d) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category after acquisition)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>e) Total (a+b+c+d)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mode of acquisition (e.g. open market / off market / public issue / rights issue / preferential allotment / inter-se transfer etc).</td>
<td>Market Purchase</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Date of acquisition</td>
<td>24 March 2020</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Equity share capital/ total voting capital of the TC before the said acquisition</td>
<td>109,971,221</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Equity share capital/ total voting capital of the TC after the said acquisition</td>
<td>109,971,221</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total diluted share/voting capital of the TC after the said acquisition</td>
<td>N/A</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

(*) Total share capital/ voting capital to be taken as per the latest filing done by the company to the Stock Exchange under Clause 5 of the listing Agreement.

(**) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants into equity shares of the TC.

Signature of the acquirer / Authorised Signatory

Jen Li  
Head of Regulatory Reporting, Asia Pacific  
Duly authorized under Powers of Attorney by and on behalf of FMR LLC & FIL Limited  
Place: C/O FIL Asia Pte Ltd, Level 21, 88 Queensway, Admiralty, Hong Kong  
Date: 26 March 2020
**Schedule**

<table>
<thead>
<tr>
<th>Fund</th>
<th>Shares held</th>
<th>% of shares and voting rights held</th>
</tr>
</thead>
<tbody>
<tr>
<td>EMERGING MARKET QDC CT T16614</td>
<td>81,700</td>
<td>0.07</td>
</tr>
<tr>
<td>NRIIT EMERG MKT GQTY T25900</td>
<td>108,000</td>
<td>0.10</td>
</tr>
<tr>
<td>ST FDS US PST STK INT OPP</td>
<td>370,333</td>
<td>0.34</td>
</tr>
<tr>
<td>FRA M FOCUSED INT SL PLT T168112</td>
<td>1,951</td>
<td>0.00</td>
</tr>
<tr>
<td>RNIT INVESTI T-An Enyg Cmpt Fund</td>
<td>2,753,666</td>
<td>1.75</td>
</tr>
<tr>
<td>TIF SERIES EMERGING MARKETS FD</td>
<td>3,590,007</td>
<td>3.20</td>
</tr>
<tr>
<td>FRA M EMERG MKT ALL CP T1682S</td>
<td>372,798</td>
<td>0.34</td>
</tr>
<tr>
<td>FRA M EMERG MKT CMX T1058</td>
<td>271,018</td>
<td>0.25</td>
</tr>
<tr>
<td>FRA M INTRINSIC OPF FND</td>
<td>50,000</td>
<td>0.05</td>
</tr>
<tr>
<td>TIF QUBL INTRINSIC VAL INV TR</td>
<td>562,800</td>
<td>0.60</td>
</tr>
<tr>
<td>TRANSITION 2 EMERG CT 151/2Z</td>
<td>997,917</td>
<td>0.85</td>
</tr>
<tr>
<td>TRANSITION 2 EMERG CT 151/2Z</td>
<td>607,711</td>
<td>0.53</td>
</tr>
<tr>
<td>TIF QUBL GROWTH &amp; VAL INV - CL B</td>
<td>9,715</td>
<td>0.01</td>
</tr>
</tbody>
</table>

**Total**                                       | 7,747,560   | 7.06                              |
BSE Limited
25th Floor, Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai 400 001
India

Fax: +91 22 2272 1919
Tel: +91 22 2272 1233 / 4, +91 22 6654 5695

26 March 2020

Dear Sir/Madam:

Enclosed please find a copy of regulatory filing for Cyient Limited.

- Regulatory filing required under regulation 29 (2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulation 2011

If you have any questions, please contact us directly by email apac.regulatory.filings@fil.com or by fax at +852 2629 9669.

Yours faithfully,

[Signature]

Regulatory Reporting, Asia Pacific

Encl.